First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
暂无分享,去创建一个
U. Jäger | L. Kenner | M. Mayerhoefer | O. Merkel | N. Prutsch | P. Staber | R. Moriggl | S. Kubicek | P. Valent | W. Sperr | S. Gültekin | B. Boidol | G. Hoermann | I. Simonitsch-Klupp | G. Hopfinger | L. Kazianka | C. Kornauth | A. Hauswirth | Marie-Bernadette Aretin | M. Panny | B. Hilgarth | E. van der Kouwe
[1] T Aittokallio,et al. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling , 2017, Leukemia.
[2] Sebastian Uhrig,et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. , 2017, Blood.
[3] O. Kallioniemi,et al. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia , 2017, Leukemia.
[4] T. Kipps,et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Sabrina,et al. Ex vivo drug response profiling detects recurrent sensitivity 1 patterns in drug resistant ALL 2 3 , 2017 .
[6] T. Kipps,et al. Phase I First-inHuman Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma , 2017 .
[7] R. Siebert,et al. Genes encoding members of the JAK‐STAT pathway or epigenetic regulators are recurrently mutated in T‐cell prolymphocytic leukaemia , 2016, British journal of haematology.
[8] T. Kipps,et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.
[9] T. Haferlach,et al. Genetic characterization of T‐PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker , 2016, Genes, chromosomes & cancer.
[10] C. Dearden. Management of prolymphocytic leukemia. , 2015, Hematology. American Society of Hematology. Education Program.
[11] Karen Cichowski,et al. Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.
[12] K. Elenitoba-Johnson,et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. , 2014, Blood.
[13] Sridhar Ramaswamy,et al. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility , 2014, Science.
[14] R. Siebert,et al. Recurrent mutation of JAK3 in T‐cell prolymphocytic leukemia , 2014, Genes, chromosomes & cancer.
[15] M. Stern,et al. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia , 2014, Leukemia.
[16] Krister Wennerberg,et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. , 2013, Cancer discovery.
[17] S. Meshinchi,et al. Development and validation of a single‐cell network profiling assay‐based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group , 2013, British journal of haematology.
[18] H. Döhner,et al. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T‐cell prolymphocytic leukemia , 2013, Cancer.
[19] D. Catovsky,et al. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. , 2011, Blood.
[20] Johannes H. Hattingh,et al. An upper bound on the total restrained domination number of a tree , 2010, J. Comb. Optim..
[21] M. Minden,et al. Dynamic Single-Cell Network Profiles in Acute Myelogenous Leukemia Are Associated with Patient Response to Standard Induction Therapy , 2010, Clinical Cancer Research.
[22] M. Teitell,et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. , 2008, Blood.
[23] B. Leber,et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] D. Catovsky,et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. , 2001, Blood.
[25] F. Sigaux,et al. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. , 1998, Blood.
[26] R. Willemze,et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] F. Sigaux,et al. MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations. , 1993, Oncogene.
[28] D. Catovsky,et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. , 1991, Blood.